Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study
| Autor: | Francisco Ruiz-Sanz, JR Valdizán-Usón, F Montañés-Rada, M López-Benito, MA Martínez-Granero, A Yusta-Izquierdo, Eddy-Ives Ls, F Mulas-Delgado, A Cánovas-Martínez, MT De Lucas-Taracena, M Garraus-Oneca, MA Idiazábal-Alecha, E Ortega-García, J Martínez-Antón, J Vaquerizo-Madrid, G Lorenzo-Sanz, P García-Magán, F Díaz-Atienza, G Ochando-Perales, Fernández-Jaén A, M García-Giral, A Pelaz-Antolín, Fernández-Pérez M, Josep Antoni Ramos-Quiroga |
|---|---|
| Přispěvatelé: | [Valdizán-Usón,JR] Unidad Trastornos Neurofuncionales, Clínica Montpellier, Zaragoza. [Cánovas-Martínez,A] Hospital Dr Peset, Valencia. [Lucas-Taracena,MT de] Hospital 12 de Octubre, Madrid. [Díaz-Atienza,F] Hospital Virgen de las Nieves, Granada. [Eddy-Ives,LS] Centre Mèdic Sant Ramon, Santa Coloma de Gramenet, Barcelona. [Fernández-Jaén,A] Hospital Universitario Quirón, Madrid. [Fernández-Pérez,M] Centro de Salud La Felguera, Langreo, Asturias. [García-Giral,M] Hospital Clínic, Barcelona. [García-Magán,P] Unidad Salud Mental, Talavera de la Reina. [Garraus-Oneca,M] Clínica Universitaria de Navarra, Pamplona. [Idiazábal-Alecha,MA] Hospital Ntra. Sra. del Pilar, Barcelona. [López-Benito,M] Centro Salud Contrueces, Gijón. [Lorenzo-Sanz,G] Hospital Ramón y Cajal, Madrid. [Martínez-Granero,MA] Complejo Hospitalario Carlos Haya, Málaga. [Montañés-Rada,F, Mulas-Delgado,F] Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid. [Ochando-Perales,G, Ortega-García,E] Hospital Universitario La Fe, Valencia. [Pelaz-Antolín,A] Complejo Asistencial Universitario de León. [Ramos-Quiroga,JA] Centro Salud Mental, Alcalá de Henares. [Ruiz-Sanz,FC] Hospital Universitari Vall d'Hebron. CIBERSAM. Department of Psychiatry and Legal Medicine. Universitat Autònoma de Barcelona. [Vaquerizo-Madrid,J] Hospital General Rio Carrión, Palencia. [Ruiz-Sanz,FC] Hospital General Rio Carrión, Palencia. [Vaquerizo-Madrid,J] Hospital Materno-Infantil, Badajoz. [Yusta-Izquierdo,A] Hospital Universitario, Guadalajara, Spain. |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Pediatrics
medicine.medical_specialty Neuropsychiatric Disease and Treatment Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids Carbocyclic::Phenylacetates::Methylphenidate [Medical Subject Headings] España Satisfaction Neurosciences. Biological psychiatry. Neuropsychiatry methylphenidate Estudios Multicéntricos como Asunto Pharmacologic treatment Attention deficit hyperactivity disorder Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Multicenter Studies as Topic [Medical Subject Headings] Named Groups::Persons::Age Groups::Adult [Medical Subject Headings] Medicine ADHD pharmacologic treatment In patient RC346-429 Adverse effect Biological Psychiatry Named Groups::Persons::Age Groups::Child [Medical Subject Headings] Original Research Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings] Trastorno por Déficit de Atención con Hiperactividad business.industry Methylphenidate Adulto Medical record satisfaction medicine.disease Psychiatry and Mental health attention deficit hyperactivity disorder El Niño Niño Clinical Global Impression Observational study Neurology. Diseases of the nervous system business Metilfenidato Psychiatry and Psychology::Mental Disorders::Mental Disorders Diagnosed in Childhood::Attention Deficit and Disruptive Behavior Disorders::Attention Deficit Disorder with Hyperactivity [Medical Subject Headings] RC321-571 medicine.drug |
| Zdroj: | Neuropsychiatric Disease and Treatment Neuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 211-218 (2013) |
| Popis: | JR Valdizán-Usón,1 A Cánovas-Martínez,2 MT De Lucas-Taracena,3 F Díaz-Atienza,4 LS Eddy-Ives,5 A Fernández-Jaén,6 M Fernández-Pérez,7 M García-Giral,8 P García-Magán,9 M Garraus-Oneca,10 MA Idiazábal-Alecha,11 M López-Benito,12 G Lorenzo-Sanz,13 J Martínez-Antón,14 MA Martínez-Granero,15 F Montañés-Rada,16 F Mulas-Delgado,17 G Ochando-Perales,18 E Ortega-García,19 A Pelaz-Antolín,20 JA Ramos-Quiroga,21 FC Ruiz-Sanz,22 J Vaquerizo-Madrid,23 A Yusta-Izquierdo241Unidad Trastornos Neurofuncionales, Clínica Montpellier, Zaragoza, 2Hospital Dr Peset, Valencia, 3Hospital 12 de Octubre, Madrid, 4Hospital Virgen de las Nieves, Granada, 5Centre Mèdic Sant Ramon, Santa Coloma de Gramenet, Barcelona, 6Hospital Universitario Quirón, Madrid, 7Centro de Salud La Felguera, Langreo, Asturias, 8Hospital Clínic, Barcelona, 9Unidad Salud Mental, Talavera de la Reina, 10Clínica Universitaria de Navarra, Pamplona, 11Hospital Ntra. Sra. del Pilar, Barcelona, 12Centro Salud Contrueces, Gijón, 13Hospital Ramón y Cajal, Madrid, 14Complejo Hospitalario Carlos Haya, Málaga, 15Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, 16Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, 17Hospital Universitario La Fe, Valencia, 18Hospital Universitario La Fe, Valencia, 19Complejo Asistencial Universitario de León, 20Centro Salud Mental, Alcalá de Henares, 21Hospital Universitari Vall d'Hebron. CIBERSAM. Department of Psychiatry and Legal Medicine. Universitat Autònoma de Barcelona, 22Hospital General Rio Carrión, Palencia, 23Hospital Materno-Infantil, Badajoz, 24Hospital Universitario, Guadalajara, SpainBackground: The purpose of this multicenter Spanish study was to evaluate the response to immediate-release methylphenidate by children and adults diagnosed with attention-deficit/hyperactivity disorder (ADHD), as well as to obtain information on current therapy patterns and safety characteristics.Methods: This multicenter, observational, retrospective, noninterventional study included 730 patients aged 4–65 years with a diagnosis of ADHD. Information was obtained based on a review of medical records for the years 2002–2006 in sequential order.Results: The ADHD predominantly inattentive subtype affected 29.7% of patients, ADHD predominantly hyperactive-impulsive was found in 5.2%, and the combined subtype in 65.1%. Overall, a significant lower Clinical Global Impression (CGI) score and mean number of DSM-IV TR (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision) symptoms by subtype were found after one year of treatment with immediate-release methylphenidate; CGI decreased from 4.51 to 1.69, symptoms of inattention from 7.90 to 4.34, symptoms of hyperactivity from 6.73 to 3.39, and combined subtype symptoms from 14.62 to 7.7. Satisfaction with immediate-release methylphenidate after one year was evaluated as “very satisfied” or “satisfied” by 86.90% of the sample; 25.75% of all patients reported at least one adverse effect. At the end of the study, 41.47% of all the patients treated with immediate-release methylphenidate were still receiving it, with a mean time of 3.80 years on therapy.Conclusion: Good efficacy and safety results were found for immediate-release methylphenidate in patients with ADHD.Keywords: attention deficit hyperactivity disorder, ADHD, pharmacologic treatment, methylphenidate, satisfaction |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|